Sonoda Akihiro, Yoshinaga Sosuke, Yunoki Kaori, Ezaki Soichiro, Yano Kotaro, Takeda Mitsuhiro, Toda Etsuko, Terashima Yuya, Matsushima Kouji, Terasawa Hiroaki
Department of Structural BioImaging, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto, 862-0973, Japan.
Department of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Mol Biotechnol. 2017 May;59(4-5):141-150. doi: 10.1007/s12033-017-0002-2.
FROUNT is a cytoplasmic protein that binds to the membrane-proximal C-terminal regions (Pro-Cs) of chemokine receptors, CCR2 and CCR5. The FROUNT-chemokine receptor interactions play a pivotal role in the migration of inflammatory immune cells, indicating the potential of FROUNT as a drug target for inflammatory diseases. To provide the foundation for drug development, structural information of the Pro-C binding region of FROUNT is desired. Here, we defined the novel structural domain (FNT-CB), which mediates the interaction with the chemokine receptors. A recombinant GST-tag-fused FNT-CB protein expression system was constructed. The protein was purified by affinity chromatography and then subjected to in-gel protease digestion of the GST-tag. The released FNT-CB was further purified by anion-exchange and size-exclusion chromatography. Purified FNT-CB adopts a helical structure, as indicated by CD. NMR line-broadening indicated that weak aggregation occurred at sub-millimolar concentrations, but the line-broadening was mitigated by using a deuterated sample in concert with transverse relaxation-optimized spectroscopy. The specific binding of FNT-CB to CCR2 Pro-C was confirmed by the fluorescence-based assay. The improved NMR spectral quality and the retained functional activity of FNT-CB support the feasibility of further structural and functional studies targeted at the anti-inflammatory drug development.
FROUNT是一种细胞质蛋白,可与趋化因子受体CCR2和CCR5的膜近端C末端区域(Pro-Cs)结合。FROUNT与趋化因子受体的相互作用在炎性免疫细胞的迁移中起关键作用,这表明FROUNT作为炎性疾病药物靶点的潜力。为药物开发提供基础,需要FROUNT的Pro-C结合区域的结构信息。在此,我们定义了介导与趋化因子受体相互作用的新型结构域(FNT-CB)。构建了重组GST标签融合的FNT-CB蛋白表达系统。该蛋白通过亲和层析纯化,然后对GST标签进行凝胶内蛋白酶消化。释放的FNT-CB通过阴离子交换和尺寸排阻色谱进一步纯化。如圆二色性所示,纯化的FNT-CB呈现螺旋结构。核磁共振谱线展宽表明在亚毫摩尔浓度下发生了弱聚集,但通过使用氘代样品并结合横向弛豫优化光谱,谱线展宽得到了缓解。基于荧光的测定证实了FNT-CB与CCR2 Pro-C的特异性结合。FNT-CB改善的核磁共振光谱质量和保留的功能活性支持了针对抗炎药物开发进行进一步结构和功能研究的可行性。